Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech's double-blind, randomized, placebo-controlled Phase III clinical evaluation of pertuzumab and trastuzumab (Cleopatra) trial has met primary endpoint.
Subscribe to our email newsletter
The results of the trial demonstrated that patients with HER2-positive metastatic breast cancer (mBC) who have been administered combined medicine of pertuzumab and Herceptin (trastuzumab), in addition to docetaxel chemotherapy, lived longer without worsening of disease than the patients who received only Herceptin and docetaxel.
Genentech investigated the safety and efficacy profile of pertuzumab in conjunction with Herceptin and docetaxel chemotherapy in comparison to Herceptin and docetaxel in patients with HER2-positive metastatic breast cancer (mBC).
Roche chief medical officer Global Product Development head Hal Barron said they plan to submit the study results for global regulatory approval this year.